Pfizer
Pfizer Inc., a leading global biopharmaceutical company headquartered in the United States, has been at the forefront of medical innovation since its founding in 1849. With a strong presence in North America, Europe, and Asia, Pfizer operates across various sectors, including vaccines, oncology, and rare diseases. The company is renowned for its core products, such as the COVID-19 vaccine and groundbreaking cancer therapies, which leverage advanced biotechnology to address unmet medical needs. Pfizer's commitment to research and development has positioned it as a market leader, consistently achieving significant milestones in drug discovery and patient care. With a robust portfolio and a reputation for quality, Pfizer continues to shape the future of healthcare, making a profound impact on global health outcomes.
DitchCarbon Score
How does Pfizer's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pfizer's score of 83 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pfizer's reported carbon emissions
In 2024, Pfizer reported total emissions of approximately 1,080,000,000 kg CO2e for Scope 1 and 2, alongside significant Scope 3 emissions, including about 188,000,000 kg CO2e from business travel and 154,000,000 kg CO2e from downstream transportation and distribution. This reflects a commitment to reducing its greenhouse gas emissions by 46% from a 2019 baseline by 2030, covering both Scope 1 and 2 emissions. Pfizer has set ambitious climate targets, including achieving net-zero emissions across its operations by 2040. This includes a commitment to procure 100% renewable electricity and a 25% reduction in Scope 3 emissions from business travel by 2025. Additionally, the company aims to reduce upstream transportation and distribution emissions by 10% by 2025. Overall, Pfizer's climate strategy is aligned with the Science Based Targets initiative, demonstrating a proactive approach to addressing climate change and reducing its carbon footprint in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | - | - | - |
| Scope 2 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | - | - | - |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pfizer is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
